 |
71 Diseases |  |
105 Trials |
|
105 Trials |  |
2830 News |  |
| «12...26272829303132333435363738» |
- Halaven (eribulin mesylate) / Eisai
New P2 trial: AOST1322: Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma (clinicaltrials.gov) - Mar 25, 2014
P2, N=33, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- ||||| Lynparza (olaparib) / Merck (MSD), AstraZeneca
Enrollment change, Monotherapy, BRCA Biomarker, PARP Biomarker, Metastases: OlympiAD: Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. (clinicaltrials.gov) - Mar 18, 2014
P3, N=2820, Recruiting, Sponsor: AstraZeneca
N=310 --> 2820
- Korlym (mifepristone) / Corcept Therap
Enrollment open, Combination therapy, Metastases: Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors (clinicaltrials.gov) - Mar 17, 2014
P1, N=40, Recruiting, Sponsor: Corcept Therapeutics
N=310 --> 2820 Not yet recruiting --> Recruiting
- Halaven (eribulin mesylate) / Eisai
New P1 trial: Study of Eribulin in Children With Cancer to Determine Safety (clinicaltrials.gov) - Mar 6, 2014
P1, N=15, Recruiting, Sponsor: University of Oklahoma
- |||| Halaven (eribulin mesylate) / Eisai
Trial completion, Metastases: Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet Chemotherapy (clinicaltrials.gov) - Feb 22, 2014
P2, N=106, Completed, Sponsor: Eisai Inc.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||| Halaven (eribulin mesylate) / Eisai
Trial completion, Metastases: A Study of E7389 in Advanced/Metastatic Breast Cancer Patients (clinicaltrials.gov) - Feb 22, 2014
P2, N=104, Completed, Sponsor: Eisai Inc.
Active, not recruiting --> Completed No longer recruiting --> Completed
- | Halaven (eribulin mesylate) / Eisai
Trial completion, Metastases: Study of E7389 Administered Once Every 3 Weeks In Patients With Advanced Solid Tumors (clinicaltrials.gov) - Feb 22, 2014
P1, N=21, Completed, Sponsor: Eisai Inc.
No longer recruiting --> Completed No longer recruiting --> Completed
- | Halaven (eribulin mesylate) / Eisai
Trial completion, Metastases: Study of E7389 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Feb 22, 2014
P1, N=33, Completed, Sponsor: Eisai Inc.
No longer recruiting --> Completed Recruiting --> Completed
- | Halaven (eribulin mesylate) / Eisai
Trial completion, Metastases: E7389 in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Feb 22, 2014
P1, N=31, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Active, not recruiting --> Completed
- Halaven (eribulin mesylate) / Eisai
Enrollment change, Metastases: Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction (clinicaltrials.gov) - Feb 20, 2014
P1/2, N=148, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=82 --> 148
- |||||| Halaven (eribulin mesylate) / Eisai
Enrollment open, Metastases: EMBRACE: Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer (clinicaltrials.gov) - Feb 16, 2014
P3, N=910, Recruiting, Sponsor: Eisai Inc.
N=82 --> 148 Not yet recruiting --> Recruiting
- | Halaven (eribulin mesylate) / Eisai
New P2a trial, Monotherapy, Metastases: MERIBEL: Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment (clinicaltrials.gov) - Feb 10, 2014
P2a, N=60, Recruiting, Sponsor: Medica Scientia Innovation Research
- ||| Halaven (eribulin mesylate) / Eisai
Enrollment closed, Combination therapy: Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer (clinicaltrials.gov) - Feb 6, 2014
P2, N=67, Active, not recruiting, Sponsor: Eisai Inc.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Halaven (eribulin mesylate) / Eisai
Enrollment closed: An Open-Label Study to Assess the Pharmacokinetics and Safety of HALAVEN in Subjects With Cancer Who Also Have Impaired Renal Function (clinicaltrials.gov) - Jan 29, 2014
P1, N=18, Active, not recruiting, Sponsor: Eisai Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Halaven (eribulin mesylate) / Eisai
Trial initiation date, Metastases: A Study of Eribulin Mesylate With Trastuzumab for Advanced or Recurrent Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer (clinicaltrials.gov) - Jan 21, 2014
P1, N=24, Active, not recruiting, Sponsor: Eisai Co., Ltd.
Recruiting --> Active, not recruiting Initiation date: Oct 2011 --> Oct 2012
- Halaven (eribulin mesylate) / Eisai
Enrollment closed, Metastases: A Study of Eribulin Mesylate With Trastuzumab for Advanced or Recurrent Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer (clinicaltrials.gov) - Jan 21, 2014
P1, N=24, Active, not recruiting, Sponsor: Eisai Co., Ltd.
Initiation date: Oct 2011 --> Oct 2012 Recruiting --> Active, not recruiting
- Halaven (eribulin mesylate) / Eisai
Enrollment open, Metastases: Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer (clinicaltrials.gov) - Jan 15, 2014
P2, N=60, Recruiting, Sponsor: University of Washington
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||||||||| Halaven (eribulin mesylate) / Eisai
New P3 trial, Metastases: EMBRACE: Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer (clinicaltrials.gov) - Jan 14, 2014
P3, N=910, Recruiting, Sponsor: Eisai Inc.
- Zoptrex (zoptarelin doxorubicin) / AEterna Zentaris
Trial termination, Metastases: Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer (clinicaltrials.gov) - Jan 13, 2014
P2, N=7, Terminated, Sponsor: AEterna Zentaris
Not yet recruiting --> Recruiting Recruiting --> Terminated; Poor recruitment
- Zoptrex (zoptarelin doxorubicin) / AEterna Zentaris
Enrollment change, Metastases: Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer (clinicaltrials.gov) - Jan 13, 2014
P2, N=7, Terminated, Sponsor: AEterna Zentaris
Recruiting --> Terminated; Poor recruitment N=74 --> 7
- | Halaven (eribulin mesylate) / Eisai, Kisqali (ribociclib) / Novartis
New P2 trial, Circulating tumor cells, Tumor cell, Metastases: DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs). (clinicaltrials.gov) - Jan 12, 2014
P2, N=400, Recruiting, Sponsor: Prof. W. Janni
- ||| Halaven (eribulin mesylate) / Eisai
Enrollment closed, Combination therapy: A Confirmation Study of Eribulin in Combination With Capecitabine (clinicaltrials.gov) - Dec 19, 2013
P1/2, N=116, Active, not recruiting, Sponsor: Eisai Limited
N=74 --> 7 Recruiting --> Active, not recruiting
- | Korlym (mifepristone) / Corcept Therap
New P1 trial, Combination therapy, Metastases: Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors (clinicaltrials.gov) - Dec 16, 2013
P1, N=40, Recruiting, Sponsor: Corcept Therapeutics
- Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open, Combination therapy, Metastases: Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer (clinicaltrials.gov) - Dec 8, 2013
P2, N=68, Recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting
- |||||||||| Lynparza (olaparib) / Merck (MSD), AstraZeneca
New P3 trial, Monotherapy, BRCA Biomarker, PARP Biomarker, Metastases: OlympiAD: Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. (clinicaltrials.gov) - Dec 2, 2013
P3, N=2820, Recruiting, Sponsor: AstraZeneca
- ||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial, Combination therapy, Metastases: 1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over. (clinicaltrials.gov) - Dec 2, 2013
P2, N=60, Not yet recruiting, Sponsor: Katherine Tkaczuk
- balixafortide (POL 6326) / Spexis
Enrollment open, Combination therapy, Metastases: Dose Escalation of POL6326 in Combination With Eribulin in Patients With Metastatic Breast Cancer (clinicaltrials.gov) - Nov 27, 2013
P1, N=24, Recruiting, Sponsor: Polyphor Ltd.
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting
- Avastin (bevacizumab) / Roche, Halaven (eribulin mesylate) / Eisai
Enrollment open, Metastases: First Line Metastatic Breast Cancer Treatment (ESMERALDA) (clinicaltrials.gov) - Nov 12, 2013
P2, N=59, Recruiting, Sponsor: ARCAGY/ GINECO GROUP
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| Halaven (eribulin mesylate) / Eisai
New P4 trial, Metastases: ESKIMO: Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - Oct 9, 2013
P4, N=100, Active, not recruiting, Sponsor: Eisai Korea Inc.
- Halaven (eribulin mesylate) / Eisai
Enrollment change, Metastases: Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies (clinicaltrials.gov) - Sep 18, 2013
P=N/A, N=9, Completed, Sponsor: Eisai Inc.
Not yet recruiting --> Recruiting N=200 --> 9
- | Avastin (bevacizumab) / Roche, Halaven (eribulin mesylate) / Eisai
New P2 trial, Metastases: First Line Metastatic Breast Cancer Treatment (ESMERALDA) (clinicaltrials.gov) - Sep 11, 2013
P2, N=59, Recruiting, Sponsor: ARCAGY/ GINECO GROUP
- ||| Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche
Enrollment closed: Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer (clinicaltrials.gov) - Sep 10, 2013
P1/2, N=56, Active, not recruiting, Sponsor: ACORN Research, LLC
N=200 --> 9 Recruiting --> Active, not recruiting
- | Halaven (eribulin mesylate) / Eisai
Enrollment closed, Metastases: Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer (clinicaltrials.gov) - Aug 28, 2013
P2, N=50, Active, not recruiting, Sponsor: National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Halaven (eribulin mesylate) / Eisai, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer (clinicaltrials.gov) - Aug 1, 2013
P1/2, N=63, Recruiting, Sponsor: howard safran
Recruiting --> Active, not recruiting N=25 --> 63
- ||||| Onzeald (etirinotecan pegol) / Nektar Therap
Enrollment closed, Metastases: The BEACON Study (Breast Cancer Outcomes With NKTR-102) (clinicaltrials.gov) - Aug 1, 2013
P3, N=840, Active, not recruiting, Sponsor: Nektar Therapeutics
N=25 --> 63 Recruiting --> Active, not recruiting
- | Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial, Combination therapy, Metastases: Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer (clinicaltrials.gov) - Jul 29, 2013
P2, N=68, Recruiting, Sponsor: Dana-Farber Cancer Institute
- | Halaven (eribulin mesylate) / Eisai
New P2 trial, Metastases: Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer (clinicaltrials.gov) - Jul 23, 2013
P2, N=60, Recruiting, Sponsor: University of Washington
- ||||| Halaven (eribulin mesylate) / Eisai
Enrollment closed: Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma (clinicaltrials.gov) - Jul 1, 2013
P3, N=450, Active, not recruiting, Sponsor: Eisai Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Halaven (eribulin mesylate) / Eisai
Enrollment open, BRCA Biomarker, Patient reported outcomes, Metastases: Eribulin in HER2 Negative Metastatic BrCa (clinicaltrials.gov) - Jun 3, 2013
P2, N=90, Recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Halaven (eribulin mesylate) / Eisai
Enrollment closed: Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients (clinicaltrials.gov) - May 13, 2013
P2, N=30, Active, not recruiting, Sponsor: Northwestern University
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | balixafortide (POL 6326) / Spexis
New P1 trial, Combination therapy, Metastases: Dose Escalation of POL6326 in Combination With Eribulin in Patients With Metastatic Breast Cancer (clinicaltrials.gov) - Apr 18, 2013
P1, N=24, Recruiting, Sponsor: Polyphor Ltd.
- Halaven (eribulin mesylate) / Eisai
Trial initiation date, Metastases: Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients (clinicaltrials.gov) - Apr 10, 2013
P2, N=37, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Initiation date: Apr 2006 --> Aug 2006
- Halaven (eribulin mesylate) / Eisai
Enrollment closed, Combination therapy, Surgery, Metastases: Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by Surgery (clinicaltrials.gov) - Apr 10, 2013
P1, N=45, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Apr 2006 --> Aug 2006 Recruiting --> Active, not recruiting
- | Halaven (eribulin mesylate) / Eisai
New P2 trial, BRCA Biomarker, Patient reported outcomes, Metastases: Eribulin in HER2 Negative Metastatic BrCa (clinicaltrials.gov) - Apr 8, 2013
P2, N=90, Recruiting, Sponsor: Dana-Farber Cancer Institute
- Halaven (eribulin mesylate) / Eisai
Enrollment open, Metastases: Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction (clinicaltrials.gov) - Mar 25, 2013
P1/2, N=148, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting
- ||||| Halaven (eribulin mesylate) / Eisai
Enrollment closed, Metastases: A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov) - Mar 2, 2013
P3, N=540, Active, not recruiting, Sponsor: Eisai Inc.
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- Kineret (anakinra) / SOBI
New P1 trial, Metastases, Immune cell: Safety and Blood Immune Cell Study of Anakinra Plus Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients (clinicaltrials.gov) - Feb 28, 2013
P1, N=20, Recruiting, Sponsor: Baylor Research Institute
- |||| Halaven (eribulin mesylate) / Eisai
Enrollment open, Combination therapy, Metastases: Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer (clinicaltrials.gov) - Feb 26, 2013
P1/2, N=95, Recruiting, Sponsor: Eisai Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting
- | Halaven (eribulin mesylate) / Eisai
New P1 trial, Combination therapy, Metastases: A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients (clinicaltrials.gov) - Feb 18, 2013
P1, N=25, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- ||| Halaven (eribulin mesylate) / Eisai
Enrollment change, Metastases: A Study of E7389 in Advanced/Metastatic Breast Cancer Patients (clinicaltrials.gov) - Feb 5, 2013
P2, N=104, Completed, Sponsor: Eisai Inc.
Active, not recruiting --> Recruiting N=61 --> 104